IDEAYA Biosciences Grants Stock Options to New Employees Following Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences Grants Stock Options to New Employees

IDEAYA Biosciences, Inc., known for its commitment to precision medicine in oncology, recently made notable strides in its workforce expansion. On June 25, 2026, the Compensation Committee of IDEAYA's Board of Directors awarded non-qualified stock options to purchase a total of 98,000 shares of common stock to four newly employed individuals. This decision was made according to the guidelines set by Nasdaq Listing Rule 5635(c)(4) in recognition of their employment agreements.

Incentives for New Talent

The stock options were given under the 2023 Employment Inducement Incentive Award Plan, specifically designed to entice new recruits who were not previously part of the company. This strategic move shows IDEAYA's determination to bring skilled professionals on board, enhancing its capabilities in discovering and developing targeted cancer therapies. The flexibility of their modern approach to human resources highlights the company's acknowledgment of the fierce competition within the biotech sector.

Understanding the Stock Options

The stock options come with an exercise price of $36.29 per share, equivalent to the closing share price at which IDEAYA's stock was trading on The Nasdaq Global Select Market on the date the options were granted. Notably, these options are structured to vest over a four-year timeline, with the first 25% becoming available after the initial anniversary of the commencement date. The subsequent 75% will vest in monthly installments over the following three years, imposing a clear incentive for employees to remain with the company and contribute significantly to its growth.

IDEAYA: A Leader in Oncology

Founded with a mission to revolutionize cancer treatment, IDEAYA Biosciences focuses on developing transformative therapies through innovative drug discovery techniques. The company's approach combines extensive expertise in small-molecule drug development, structural biology, and bioinformatics to create targeted therapies that align with the genetic drivers of various cancers. With a robust pipeline emphasizing synthetic lethality and antibody-drug conjugates (ADCs), IDEAYA is poised to bring groundbreaking oncology treatments to the market.

Commitment to Precision Medicine

A vital component of IDEAYA’s mission is its dedication to precision oncology — offering personalized treatment options by identifying and validating translational biomarkers. The overall goal is clear: to effectively alter the course of the disease and improve clinical outcomes for cancer patients. This patient-centered perspective keeps IDEAYA ahead in the rapidly changing landscape of cancer treatments.

As IDEAYA continues to expand its talent pool and develop cutting-edge therapeutics, the actions taken today, including the induction grants to new team members, mark a significant commitment to pushing the boundaries of oncology care.

For more information about IDEAYA and their initiatives in precision medicine, you can contact:
Joshua Bleharski, Ph.D., Chief Financial Officer
[email protected]